date/time interval
- 2013-04-01 - 2014-04-01
A phase III clinical trial to study the tolerability and immunogenicity of V503, a multivalent human papillomavirus (HPV) L1 virus-like particle (BLP) vaccine, in 16- to 26-year-olds and 16- to 26-year-olds in women V5003-003-0069
Grant
- Overview
- Affiliation
- View All
Overview
Affiliation
contributor
- Ruíz Sternberg, Ángela María Principal Investigator